Business
Karyopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100 Million
− Investment Expected to Extend Karyopharm's Cash Runway into the Middle of 2023 - − Agreement Follows a Prior $75M Investment by Healthcare Royalty in
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"− Investment Expected to Extend Karyopharm's Cash Runway into the Middle of 2023 -\n − Agreement Follows a Prior $75M Investment by Healthcare Royalty in Karyopharm in September 2019 -\n\n\n NEWTON, Mass., June 24, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the expansion of its royalty agreement with entities managed by HealthCare Royalty Management, LLC (HCR) for up to $100 million in new financing to support the ongoing development and commercialization of XPOVIO® (selinexor), the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, and for the clinical development of Karyopharm's other programs, including eltanexor. XPOVIO is currently marketed in the U.S. for multiple hematologic malignancy indications and has received conditional marketing authorization by the European Commission for patients with heavily pretreated multiple myeloma. Eltanexor is currently being investigated for the treatment of patients with refractory myelodysplastic syndrome.\nUnder the terms of the amended agreement, Karyopharm received $60 million and is eligible to receive two additional $20 million payments subject to certain prespecified future development and commercial milestones. HCR will receive tiered royalty payments based on worldwide net revenues of XPOVIO and any other future products. This expanded agreement follows a previous investment of $75 million that HCR made in Karyopharm in September 2019. \nKaryopharm expects that the $60 million received from HCR under this expanded royalty agreement, combined with its existing cash, cash equivalents and investments, and the cash expected to be generated from product sales, will be sufficient to fund its operations into the middle of 2023. \n\"We are thrilled to expand our relationship with HCR and this additional non-dilutive financing provides Karyopharm with immediate and substantial capital to support the ongoing commercialization and clinical development of XPOVIO and our other products in future cancer indications, including in a variety of high unmet need solid tumor settings,\" said Richard Paulson, MBA, President and Chief Executive Officer of Karyopharm. \"As we continue to make progress on our commercialization efforts, we are delighted to...